Smitha Krishnamurthi

@KimmieNgMD @ARosen380 @washingtonpost @DanaFarber @DanaFarberNews @DFarberYoungCRC @ASCO So well- deserved Kimmie! Congratulations!

Still pinching myself that I am included in the @washingtonpost Next 50 list this year! Trying every day to live up to this honor and help as many patients as I can! @DanaFarber @DanaFarberNews @DFarberYoungCRC @ASCO washingtonpost.com/post-next/inte…

“You’re too young” is not a diagnosis. Colorectal cancer is now the leading cause of cancer death for men and women under 50. It is one of the only major cancers still increasing in incidence. This is not a future problem. This is already here. A few things that matter: • Screening works. Average-risk screening starts at 45, earlier if you have risk factors. • Symptoms in young people are real and should never be brushed off. • New rectal bleeding, constipation, diarrhea, bowel habit changes, abdominal pain, or unexplained anemia are warning signs. If symptoms are new or persistent, push for evaluation. If you’re eligible, get screened. If someone you know is being dismissed, advocate for them. wsj.com/health/healthc…

As of today, the United States has officially left the World Health Organization. We’ll look back on this as a grave error. Health threats do not respect borders, and weakening global cooperation makes Americans less safe.

@CathyEngMD @ASCO @KimrynRathmell @NVijayvergiaMD @JJSingleton1 @rutikamehtaMD @KristenCiombor @NCCN @eaonc @SWOG Highlight of my meeting is seeing you and so many incredibly dedicated people fighting and surviving cancer!

Day 1 of @ASCO #GI26 always honored to have so many of these amazing individuals as friends/colleagues. ONE mission = OMIT #cancer @KimrynRathmell #crystaldenlinger @smitha42 @NVijayvergiaMD @JJSingleton1 @rutikamehtaMD @KristenCiombor @NCCN @eaonc @SWOG #CancerResearch

Congrats @cagirlinchi and @manjuggm and @colontown on this work! Great time saving option for patients. So happy I got to see you both at #ASCOGI26 !

Colorectal cancer research at #ASCOGI26: Patients are more willing than physicians to trade some survival for better quality of life—like oral-only treatment or fewer side effects. Poster by @DanaFarber’s @ThejusJay. asco.org/abstracts-pres…

#GI26 BREAKWATER Encorafenib+Cetuximab+FOLFIRI met primary ORR endpoint (64.4% vs 39.2% for 1L FOLFIRI/Bev). Data immature on everything else, but I’m going to be offering it next week to one of my pts unfortunately with early recurrence after adjuvant FOLFOX. #BRAFV600E

Our new data #ASCOGI26 led by @YoussefBouferra showing prolonged period of symptoms before diagnosis in younger people with colorectal cancer compared to usual-onset. Greater awareness and targeted screening approaches urgently needed.

My editorial on new US inpatient data re cancer-associated VTE by Maiocco et al is now out @RPTHjournal Key findings: VTE 📈 mortality, LOS, costs Solutions: nationwide registry as advocated by @StopTheClot, better prevention strategies, infrastructure sciencedirect.com/science/articl…

You are a wonderful addition to Colon Task Force @ronanhsieh ! We will all benefit from your thoughtful analyses and opinions!

@marklewismd You daughter is an incredible artist. I thought it was a photo. I’m so sorry for your loss.

My daughter drew this portrait of our dog that just died and I think I have something in my eye

@AnwaarSaeed3 @CathyEngMD @KimmieNgMD @PancPathologist @MaenAbdelrahim @DennisJHsu @JanieYZhang @JohnRheeMD @UPMCHillmanCC It was a fantastic meeting @AnwaarSaeed3 ! Don’t know how you do it all!

A wonderful 3rd Annual Pittsburgh GI Cancer Summit. Deeply grateful to our sponsors and to all of our exceptional speakers for making it a success. 😇 @CathyEngMD @KimmieNgMD @smitha42 @PancPathologist @MaenAbdelrahim @DennisJHsu @JanieYZhang @JohnRheeMD @UPMCHillmanCC @UPMCPhysicianEd

@JessicaElAsmar @moaathmustafaal @ccfhemonc Congrats Jessica! 👏🏽👏🏽👏🏽

Couldn’t have done it without the inspiring mentorship of Dr. @moaathmustafaal, and our team’s hard work! 🤓 @ccfhemonc

@SWexner @MedStarHealth @Georgetown @AmCollSurgeons @MedStarWHC @SAGES_Updates @ASCRS_1 @juliomayol @NeilFlochMD @ACPGBI @escp_tweets @SurgJournal @ivanoransky @DrMarcSiegel Congratulations Steve! Your legacy is amazing.

Excited, energized, and eager to start my new role on November 1, 2025 as inaugural Physician Executive Director and System Chief for Colorectal Surgery and Vice Chair for Professional Development for the Department of Surgery @MedStarHealth @Georgetown @AmCollSurgeons

Congrats Neena! 👏🏽👏🏽👏🏽

@MDmanishshah 🙏🏾

Thank you! We will have you on to talk about immunotherapy in MSS CRC! @smitha42 #CancerCast

Congrats on your podcast @MDmanishshah !

cT3/T4 per CT identifies patients with dMMR colon cancer with substantial risk of recurrence despite FOLFOX: cT3N0: 84% 3-year DFS cT4N0: 70% 3-year DFS Of course, NICHE2 : 100% 3-year DFS for cT3/4 For patients with dMMR colon cancer cT3/T4 by CT: we should discuss risks and benefits of neoadjuvant IO vs surgery and adjuvant therapy. We should recommend neoadjuvant IO for cT4N0.

Great work. Same rational to support combos RAS inhib + chemo to tackle polyclonal resistance to RASi in PDAC. Folks making point about small difference in ORR in 1L PDAC 6236 vs 6236 + chemo need to wait to see PFS data not yet released for 1L.

Congratulations to @AnwaarSaeed3, all investigators and study team on STELLAR-003! First phase III to show an OS benefit of immunotherapy in metastatic pMMR CRC. From CAMILLA to STELLAR Anwaar, your intellect and perseverance have been a joy to witness. 👏🏽👏🏽👏🏽